MarketCap
Facebook
X
TelegramAnnual report 2022
added 07-25-2022
Taro Pharmaceutical Industries Ltd. Operating Income 2011-2026 | TARO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Taro Pharmaceutical Industries Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.5 M | -414 M | 247 M | 296 M | 303 M | 515 M | 614 M | 528 M | 430 M | 329 M | - | 204 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 614 M | -414 M | 283 M |
Quarterly Operating Income Taro Pharmaceutical Industries Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 66.2 M | - | - | - | 33.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.2 M | 33.4 M | 49.8 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B |  Britain |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 34.55 | 2.04 % | $ 2.29 B |  USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 5.8 | 13.28 % | $ 391 B | Britain |
 |
Aligos Therapeutics
ALGS
|
-88 M | $ 6.68 | -12.79 % | $ 66 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 309.66 | -3.27 % | $ 40.6 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 22.88 | 4.91 % | $ 1.07 B | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 102.92 | 0.78 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-50.5 M | $ 1.15 | 7.48 % | $ 14 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.41 | 4.07 % | $ 363 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.32 | 1.41 % | $ 462 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.53 | 1.41 % | $ 3.12 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.96 | 6.1 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
-172 M | $ 3.44 | -2.27 % | $ 346 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.6 | -0.62 % | $ 426 M | Britain |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.86 | 0.39 % | $ 5.79 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |